Literature DB >> 23149497

Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States.

Michael A Acker1, Francis D Pagani, Wendy Gattis Stough, Douglas L Mann, Mariell Jessup, Robert Kormos, Mark S Slaughter, Timothy Baldwin, Lynne Stevenson, Keith D Aaronson, Leslie Miller, David Naftel, Clyde Yancy, Joseph Rogers, Jeffrey Teuteberg, Randall C Starling, Bartley Griffith, Steven Boyce, Stephen Westaby, Elizabeth Blume, Peter Wearden, Robert Higgins, Michael Mack.   

Abstract

The incorporation of complex medical device technologies into clinical practice is governed by critical oversight of the US Food and Drug Administration. This regulatory process requires a judicious balance between assuring safety and efficacy, while providing efficient review to facilitate access to innovative therapies. Recent contrasting views of the regulatory process have emphasized the difficulties in obtaining an optimal balance. Mechanical circulatory support has evolved to become an important therapy for patients who have advanced heart failure with the advent of more durable, implantable ventricular assist devices. The regulatory oversight of these new technologies has been difficult owing to the complexities of these devices, associated adverse event profile, and severity of illness of the intended patient population. Maintaining a regulatory environment to foster efficient introduction of safe and effective technologies is critical to the success of ventricular assist device therapy and the health of patients with advanced heart failure. Physicians representing key surgical and cardiology societies, and representatives from the Food and Drug Administration, National Heart, Lung, and Blood Institute, Centers for Medicare and Medicaid Services, Interagency Registry of Mechanically Assisted Circulatory Support, and industry partners gathered to discuss relevant issues regarding the current regulatory environment assessing ventricular assist devices. The goal of the meeting was to explore innovative ways to foster the introduction of technologically advanced, safe, and effective ventricular assist devices. The following summary reflects opinions and conclusions endorsed by The Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, Heart Failure Society of America, International Society for Heart and Lung Transplantation, and Interagency Registry of Mechanically Assisted Circulatory Support.

Entities:  

Mesh:

Year:  2012        PMID: 23149497     DOI: 10.1161/HHF.0b013e318279f6b5

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  2 in total

1.  The CentriMag centrifugal blood pump as a benchmark for in vitro testing of hemocompatibility in implantable ventricular assist devices.

Authors:  Chris H H Chan; Ina Laura Pieper; Rebecca Hambly; Gemma Radley; Alyssa Jones; Yasmin Friedmann; Karl M Hawkins; Stephen Westaby; Graham Foster; Catherine A Thornton
Journal:  Artif Organs       Date:  2014-07-28       Impact factor: 3.094

2.  Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent: The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) Randomized Clinical Trial.

Authors:  Daniel J Goldstein; Yoshifumi Naka; Douglas Horstmanshof; Ashwin K Ravichandran; Jacob Schroder; John Ransom; Akinobu Itoh; Nir Uriel; Joseph C Cleveland; Nirav Y Raval; Rebecca Cogswell; Erik E Suarez; Brian D Lowes; Gene Kim; Pramod Bonde; Farooq H Sheikh; Poornima Sood; David J Farrar; Mandeep R Mehra
Journal:  JAMA Cardiol       Date:  2020-04-01       Impact factor: 14.676

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.